Panel: Pricing Dilemma Divides Industry Stakeholders
Drug pricing has become the most contentious issue in the pharma world over the last two years as politics has dragged the subject into the mainstream conversation. Yet, even those within the industry have different ideas on how the problem can be fixed.
You may also be interested in...
Pfizer and Cipla have separately committed to expanding access to affordable oncology drugs in sub-Saharan Africa in collaboration with the American Cancer Society and the Clinton Health Access Initiative. The public-private alliances are expected to enable procurement of these medicines for the African nations at significant savings, which Cipla tells Scrip could be in the region of 20-30% initially.
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.